Extracellular RNA Markers of Liver Disease and Cancer
Reason given: Ran out of funds
Key facts
- Where
- Chicago, Jacksonville, Richmond, and Rochester, United StatesSee the 4 sites
Where in United States
- The University of Chicago Medical CenterChicago, United StatesNo longer taking part
- Mayo Clinic FloridaJacksonville, United StatesNo longer taking part
- McGuire VA Medical CenterRichmond, United StatesNo longer taking part
- Mayo ClinicRochester, United StatesNo longer taking part
Trial details
- Who runs it
- Mayo Clinic
- Trial code
- NCT02908048
- Record updated
- 5 May 2026
- Original description
The study will examine and evaluate the use of extracellular RNA in blood as markers for the diagnosis of liver disease or cancer, and as markers for prediction of response to treatment or recurrence of cancer after surgeryRead full original descriptionShow less
The study will examine and evaluate the use of extracellular RNA in blood as markers for the diagnosis of liver disease or cancer, and as markers for prediction of response to treatment or recurrence of cancer after surgery
Inclusion: Lab results from within the previous 90 days; Diagnosis of HCC or biliary tract cancer; Diagnosis of cirrhosis based on histology, imaging, or ultrasound; Diagnosis of a chronic liver disease without cirrhosis.
Exclusion: Prior solid organ transplant; Prior solid organ transplant; Previous or current cancer history within the past 5 years (excluding non-melanoma skin cancer); Previous cancer history with the last 5 years (excluding non-melanoma skin cancer), participation in a treatment trial for HCC.